Max Healthcare Board Approves Expansion and Financial Results

Max Healthcare Institute Limited’s board approved the Q3 FY26 financial results and an amendment to their services agreement. This amendment facilitates the addition of ~260 beds at Max Super Speciality Hospital, Dwarka. The hospital currently has ~300 beds and reported occupancy above 70% in Q3 FY26. The refundable security deposit of ~₹25 Crore will be funded through internal accruals and is expected to strengthen their footprint in Delhi NCR.

Financial Performance

The board of directors approved the unaudited standalone and consolidated financial results for Q3 FY26, ending December 31, 2025. These results were reviewed by the audit committee.

Capacity Expansion at Dwarka Hospital

An amendment to the existing services agreement was approved to extend the arrangement to approximately 260 additional beds being constructed by MHPL at the same site as the existing 300-bedded Max Super Speciality Hospital, Dwarka. Max Dwarka reported an occupancy of over 70% in Q3 FY26.

Key Financial Figures (Consolidated)

Total Income for Q3 FY26 reached ₹2,112.90 million compared to ₹1,901.61 million in Q3 FY25. Total expenses amounted to ₹1,700.12 million for Q3 FY26 compared to ₹1,519.11 million for the same period last year. Profit before tax for the period was ₹364.54 million compared to ₹308.87 million in the previous year.

Key Financial Figures (Standalone)

Standalone total income for Q3 FY26 was ₹794.24 million compared to ₹789.41 million in Q3 FY25. Profit before tax stood at ₹225.20 million compared to ₹198.18 million in the prior year’s corresponding quarter.

Details of the Expansion

The additional ~260 beds are expected to be added within the next 24 months. The expansion will be funded through a refundable security deposit of approximately ₹25 Crore using internal accruals. This expansion aims to strengthen Max Healthcare’s presence in Delhi NCR.

Source: BSE

Previous Article

PVR INOX Board Approves Q3 2026 Financial Results

Next Article

Jubilant Ingrevia Q3 FY26 Results Show Resilience Amidst Pricing Pressures